A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy
← catalyst calendarNCT07047820 · readout in 5 d
Sponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-30 | actual | When the study began enrolling |
| Primary completion | 2026-08-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-24 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Depression, Postpartum
Intervention
- Drug: Zuranolone — also filed as Zurzuvae, BIIB125
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in Edinburgh Postnatal Depression Scale (EPDS) at Day 15
measured Baseline (Day 0), Day 15
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed